Michael David Banov MD DFAPA,CPI
Medical Director of PsychAtlanta, PsychAtlanta Ketamine, and PsychAtlanta Research
Join to View Full Profile
1012 Coggins PlaceMarietta, GA 30060
Phone+1 770-422-2009
Fax+1 770-428-0330
Dr. Banov is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Michael Banov is a Psychiatrist in Marietta and Alpharetta GA. He received his medical degree from Emory University School of Medicine and has been in practice 28 years. He specializes in treatment resistant depression and other refractory psychiatric conditions utilizing novel pharmacological therapies including ketamine, Spravato, and TMS. He has been conducting clinical trials for over 25 years and has published extensively on new treatments for psychiatric conditions.
Education & Training
Mass General Brigham/Massachusetts General Hospital/McLean HospitalResidency, Psychiatry, 1990 - 1993
Boston University Medical CenterInternship, Internal Medicine, 1989 - 1990
Emory University School of MedicineClass of 1989
Certifications & Licensure
GA State Medical License 1994 - 2025
American Board of Psychiatry and Neurology Psychiatry
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification RcopiaMU EHR, DrFirst.com, Inc., 2013
Clinical Trials
- Treatment-Resistant Depression Registry Start of enrollment: 2006 Jan 01
- Vayarin® Medical Food Study for Adults With Attention Deficit Hyperactivity Disorder (ADHD) Start of enrollment: 2014 Oct 01
- Safety and Efficacy Study of SHP465 in Children and Adolescents Aged 6-17 Years With Attention-Deficit Hyperactivity Disorder (ADHD) Start of enrollment: 2015 Jun 18
Publications & Presentations
PubMed
- Suicide characteristics in patients with marked treatment-resistant major depressive disorder: A RECOVER trial report.Victoria C de Leon, Rebecca M Allen, João Quevedo, Patricio Riva-Posse, Scott T Aaronson
Journal of Affective Disorders. 2025-04-01 - 3 citationsVagus nerve stimulation in treatment-resistant depression: A one-year, randomized, sham-controlled trial.Charles R Conway, Scott T Aaronson, Harold A Sackeim, Mark S George, John Zajecka
Brain Stimulation. 2024-12-18 - 2 citationsSwitching to Intranasal Esketamine Maintains the Antidepressant Response to Intravenous Racemic Ketamine Administration: A Case Series of 10 Patients.Michael D Banov, Rachel E Landrum, Michelle B. Moore, Steven T. Szabo
Journal of Clinical Psychopharmacology. 2021-08-13
Press Mentions
Is Ketamine a Safe at-Home Treatment for Depression?May 12th, 2023- Ketamine Has Become an at-Home Treatment for Depression, but Some Scientists Say That Set-up Is Too RiskyFebruary 23rd, 2023
- Industry Briefs November 2022November 22nd, 2022
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
